A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol

@inproceedings{Shamash2011AMR,
  title={A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol},
  author={Jonathan Shamash and Thomas Powles and S-J Sarker and Andrew Protheroe and N. Mithal and Reversa Mills and Raimon L. Beard and Peter G. Wilson and N Tranter and Nikki Catherine O'Brien and S Mcfaul and T. Emerson Oliver},
  booktitle={British Journal of Cancer},
  year={2011}
}
Background:The role of further hormone therapy in castration-resistant prostate cancer (CRPC) remains unclear. We performed a multi-centre randomised phase III study comparing the use of Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol (DAiS) vs Dexamethasone, Aspirin, and deferred (until disease progression) addition of Diethylstilbestrol (DAdS).Methods:From 2001 to 2008, 270 men with chemotherapy-naive CRPC were randomly assigned, in a 1 : 1 ratio, to receive either DAiS… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

The resurgence of estrogens in the treatment of castration-resistant prostate cancer

  • Indian journal of urology : IJU : journal of the Urological Society of India
  • 2019
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis.

  • American journal of translational research
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Genetically engineered T cells for cancer immunotherapy

Dan Li, Xue Li, +8 authors Wei Wang
  • Signal Transduction and Targeted Therapy
  • 2019

Estrogens and prostate cancer

  • Prostate Cancer and Prostatic Diseases
  • 2018

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 1 EXCERPT